Siena Mantooth

College of Engineering

Works (7)

Updated: June 12th, 2024 05:01

2024 journal article

Characterization of an Injectable Chitosan Hydrogel for the Tunable, Localized Delivery of Immunotherapeutics

ACS BIOMATERIALS SCIENCE & ENGINEERING, 10(2), 905–920.

By: S. Mantooth n, A. Hancock n, P. Thompson n, P. Varghese n, D. Meritet n, M. Vrabel n, J. Hu n, D. Zaharoff n

author keywords: hydrogel; chitosan; immunotherapy; intratumoral
TL;DR: The goal of the present work was to construct a novel, injectable hydrogel that could be tuned for localized immunotherapy delivery and displayed several clinically important features, including injectability, biocompatibility, and imageability. (via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being (OpenAlex)
Sources: Web Of Science, NC State University Libraries, ORCID
Added: March 4, 2024

2024 review

Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies

[Review of ]. FRONTIERS IN IMMUNOLOGY, 15.

By: S. Mantooth n, Y. Abdou*, A. Saez-Ibanez*, S. Upadhaya* & D. Zaharoff n

author keywords: breast cancer; cancer immunotherapy; intratumoral; localized delivery; neoadjuvant; hydrogel; delivery systems
Source: Web Of Science
Added: June 11, 2024

2023 journal article

Focal Cryo-Immunotherapy with Intratumoral IL-12 Prevents Recurrence of Large Murine Tumors

CANCERS, 15(8).

By: M. Vrabel n, J. Schulman n, F. Gillam n, S. Mantooth n, K. Nguyen n & D. Zaharoff n

author keywords: focal ablation; cryoablation; IL-12; intratumoral; immunotherapy; abscopal response; checkpoint therapy
TL;DR: Cryo-immunotherapy with localized CS/IL-12 reduces recurrences and enhances the elimination of large primary tumors, and induces significant but limited systemic antitumor immunity. (via Semantic Scholar)
Source: Web Of Science
Added: May 15, 2023

2022 journal article

Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2

FRONTIERS IN IMMUNOLOGY, 13.

By: K. Nguyen n, S. Mantooth n, M. Vrabel n & D. Zaharoff n

author keywords: Intranasal vaccination; COVID-19; mucosal immunity; SARS-CoV-2; Receptor binding domain (RBD); chitosan; CpG
MeSH headings : Animals; Antibody Formation; COVID-19 / prevention & control; COVID-19 Vaccines; Humans; Immunoglobulin G; Mice; SARS-CoV-2; Vaccines, Subunit
TL;DR: Data indicate that the designed vaccine platform is versatile, adaptable and capable of overcoming key constraints of current COVID-19 vaccines. (via Semantic Scholar)
Source: Web Of Science
Added: May 31, 2022

2021 article

INJECTABLE CHITOSAN HYDROGEL FOR LOCALIZED DELIVERY OF IMMUNE CHECKPOINT INHIBITORS

Mantooth, S., Zaharoff, D., & Mantooth, S. (2021, November). JOURNAL FOR IMMUNOTHERAPY OF CANCER, Vol. 9, pp. A281–A281.

By: S. Mantooth n, D. Zaharoff n & S. Mantooth n

TL;DR: A novel injectable chitosan hydrogel was found to provide sustained release of a large model protein over a 1–2 week period with favorable in vitro kinetics and can be engineered to provide faster or slower release as needed. (via Semantic Scholar)
Source: Web Of Science
Added: April 18, 2022

2021 article

ONCO-IMMUNOLOGICAL MECHANISMS OF FOCAL ABLATION AND LOCALIZED IL-12 IMMUNOTHERAPY

Vrabel, M., Zaharoff, D., & Mantooth, S. (2021, November). JOURNAL FOR IMMUNOTHERAPY OF CANCER, Vol. 9, pp. A650–A650.

By: M. Vrabel n, D. Zaharoff n & S. Mantooth n

TL;DR: In the spontaneously metastatic LLC model, delivering CS/IL-12 two days before treatment, either resection or cryoablation, reduced the number of metastatic lung nodules and furthermore prevented the recurrence of the primary tumor after resection. (via Semantic Scholar)
Source: Web Of Science
Added: April 18, 2022

2021 journal article

Safety and Pharmacokinetics of Intravesical Chitosan/Interleukin-12 Immunotherapy in Murine Bladders

BLADDER CANCER, 7(4), 427–437.

By: K. Nguyen n, E. Wagner n, M. Vrabel n, S. Mantooth n, D. Meritet n & D. Zaharoff n

author keywords: Bladder cancer; Interleukin-12; immunotherapy; chitosan; intravesical
TL;DR: The lack of cystitis and acute inflammation justifies continued investigation of intravesical CS/IL-12 immunotherapy in larger animals and patients with bladder cancer. (via Semantic Scholar)
Source: Web Of Science
Added: January 10, 2022

Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.

Certain data included herein are derived from the Web of Science© and InCites© (2024) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.